Trial NCT06917079
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
- Phase
- Phase 1
- Sponsor
- TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
- Conditions
- Non-Small Cell Lung Cancer; NSCLC; PDAC - Pancreatic Ductal Adenocarcinoma; CRC (Colorectal Cancer); Metastatic Non-Small Lung Cell Cancer; Metastatic Colorectal Cancer (CRC); KRAS G12A; KRAS G12C; KRAS G12D; KRAS G12S; KRAS G12V; Metastatic Pancreatic Ductal Adenocarcinoma; Advanced Lung Carcinoma; Solid Tumor, Adult
- Ages
- 18+ years
Eligibility criteria
Highlighted: restrictions our model extracted, each a verbatim quote (pink = excludes outright, blue = only under conditions).
Inclusion Criteria:
* Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation
* Measurable disease by RECIST v1.1
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1Performance status
* Life expectancy >24 weeks
* Adequate organ function
Exclusion Criteria:
* Malignancy within the last 2 years as specified in the protocolPrior malignancy
* Untreated brain metastasesBrain metastases
Other inclusion/exclusion criteria are specified in the protocol.
Restrictions found (3)
- Brain metastasesConditionalexclusionShow in the text
- Performance statusConditionalinclusion
ECOG PS 0-1
Show in the text - Prior malignancyConditionalexclusion
within 2 years
Show in the text
Recruiting in Massachusetts
- Massachusetts General Hospital · Boston, Suffolk County